Physicians need to contemplate whether or not their people with underlying NAION threat elements may very well be adversely influenced by use of PDE5 inhibitors. People who have presently experienced NAION are at improved risk of NAION recurrence. Consequently, PDE5 inhibitors, such as LEVITRA, should be made use of with caution in these clients an